Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.70 |
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.60 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.54 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1570694 | 0.84 | PARP1 (0.72) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| SCHEMBL5469274 | 0.82 | PARP1 (1.00) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| Toluene SCHEMBL28109129 | 0.79 | PARP1 (0.60) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| SCHEMBL27923545 | 0.78 | SLC22A12 (0.78) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| SCHEMBL8877952 | 0.78 | PARP1 (0.59) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| SCHEMBL29831328 | 0.78 | PARP1 (0.59) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| Acetic Acid SCHEMBL28057186 | 0.76 | PARP1 (0.57) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| SCHEMBL28955072 | 0.76 | SLC22A12 (1.00) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| SCHEMBL28857679 | 0.75 | SLC22A12 (1.00) | PARP1SLC22A12SLC22A6ABCG2ENPP1 | |
| Quinoline SCHEMBL27783727 | 0.74 | NOTUM (0.71) | PARP1SLC22A12ENPP1NOTUMCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809668-A1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-12-10 | — | — | EP | disclosed |
| WO-2013114332-A1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-08 | — | — | WO | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| CN-102584830-A | Dihydroindene amide compounds, and medicinal composition and application thereof | BEIJING SAILINTAI PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-07-18 | — | — | CN | disclosed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | PARP1 769/4885SLC22A12 876/4885SLC22A6 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.